Selenoprotein P Status Correlates to Cancer-Specific Mortality in Renal Cancer Patients

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Meyer, Hellmuth A ^a   Endermann, Tobias ^a   Stephan, Carsten ^a,b   Stoedter, Mette ^a   Behrends, Thomas ^a   Wolff, Ingmar ^a   Jung, Klaus ^a,b   Schomburg, Lutz ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Berlin Institute for Urologic Research   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

SELENIUM; SELENOPROTEIN P; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER GRADING; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL ASSESSMENT; CONTROLLED STUDY; FEMALE; HUMAN; KIDNEY CANCER; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SELENIUM; SELENOPROTEIN P;

EID: 84867285087     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046644     Document Type: Article

References (52)

1. Papp LV, Lu J, Holmgren A, Khanna KK, (2007) From selenium to selenoproteins: synthesis, identity, and their role in human health. Antioxid Redox Signal 9: 775-806.
2. Lobanov AV, Hatfield DL, Gladyshev VN, (2009) Eukaryotic selenoproteins and selenoproteomes. Biochim Biophys Acta 1790: 1424-1428.
3. Lescure A, Rederstorff M, Krol A, Guicheney P, Allamand V, (2009) Selenoprotein function and muscle disease. Biochim Biophys Acta 1790: 1569-1574.
4. Schweizer U, Dehina N, Schomburg L, (2011) Disorders of selenium metabolism and selenoprotein function. Curr Opin Pediatr 23: 429-435.
5. Hesketh J, (2008) Nutrigenomics and selenium: gene expression patterns, physiological targets, and genetics. Annu Rev Nutr 28: 157-177.
6. Combs GF Jr, Watts JC, Jackson MI, Johnson LK, Zeng H, et al. (2011) Determinants of selenium status in healthy adults. Nutr J 10: 75.
7. Curran JE, Jowett JB, Elliott KS, Gao Y, Gluschenko K, et al. (2005) Genetic variation in selenoprotein S influences inflammatory response. Nat Genet 37: 1234-1241.
8. Peters U, Chatterjee N, Hayes RB, Schoen RE, Wang Y, et al. (2008) Variation in the selenoenzyme genes and risk of advanced distal colorectal adenoma. Cancer Epidemiol Biomarkers Prev 17: 1144-1154.
9. Steinbrecher A, Meplan C, Hesketh J, Schomburg L, Endermann T, et al. (2010) Effects of selenium status and polymorphisms in selenoprotein genes on prostate cancer risk in a prospective study of European men. Cancer Epidemiol Biomarkers Prev 19: 2958-2968.
10. Rayman MP, (2009) Selenoproteins and human health: insights from epidemiological data. Biochim Biophys Acta 1790: 1533-1540.
11. Zhuo P, Diamond AM, (2009) Molecular mechanisms by which selenoproteins affect cancer risk and progression. Biochim Biophys Acta 1790: 1546-1554.
12. Bermano G, Pagmantidis V, Holloway N, Kadri S, Mowat NA, et al. (2007) Evidence that a polymorphism within the 3′UTR of glutathione peroxidase 4 is functional and is associated with susceptibility to colorectal cancer. Genes Nutr 2: 225-232.
13. Penney KL, Schumacher FR, Li H, Kraft P, Morris JS, et al. (2011) A large prospective study of SEP15 genetic variation, interaction with plasma selenium levels, and prostate cancer risk and survival. Cancer Prev Res (Phila) 3: 604-610.
14. Corpet DE, Pierre F, (2005) How good are rodent models of carcinogenesis in predicting efficacy in humans? A systematic review and meta-analysis of colon chemoprevention in rats, mice and men. Eur J Cancer 41: 1911-1922.
15. Ip C, Dong Y, Ganther HE, (2002) New concepts in selenium chemoprevention. Cancer Metastasis Rev 21: 281-289.
16. Sanmartin C, Plano D, Palop JA, (2008) Selenium compounds and apoptotic modulation: a new perspective in cancer therapy. Mini Rev Med Chem 8: 1020-1031.
17. Arner ES, Holmgren A, (2006) The thioredoxin system in cancer. Semin Cancer Biol 16: 420-426.
18. Kellen E, Zeegers M, Buntinx F, (2006) Selenium is inversely associated with bladder cancer risk: a report from the Belgian case-control study on bladder cancer. Int J Urol 13: 1180-1184.
19. Yu MW, Horng IS, Hsu KH, Chiang YC, Liaw YF, et al. (1999) Plasma selenium levels and risk of hepatocellular carcinoma among men with chronic hepatitis virus infection. Am J Epidemiol 150: 367-374.
20. Jacobs ET, Jiang R, Alberts DS, Greenberg ER, Gunter EW, et al. (2004) Selenium and colorectal adenoma: results of a pooled analysis. J Natl Cancer Inst 96: 1669-1675.
21. Vogt TM, Ziegler RG, Graubard BI, Swanson CA, Greenberg RS, et al. (2003) Serum selenium and risk of prostate cancer in U.S. blacks and whites. Int J Cancer 103: 664-670.
22. Burk RF, Hill KE, (2009) Selenoprotein P-expression, functions, and roles in mammals. Biochim Biophys Acta 1790: 1441-1447.
23. Hurst R, Armah CN, Dainty JR, Hart DJ, Teucher B, et al. (2010) Establishing optimal selenium status: results of a randomized, double-blind, placebo-controlled trial. Am J Clin Nutr 91: 923-931.
24. Xia Y, Hill KE, Li P, Xu J, Zhou D, et al. (2010) Optimization of selenoprotein P and other plasma selenium biomarkers for the assessment of the selenium nutritional requirement: a placebo-controlled, double-blind study of selenomethionine supplementation in selenium-deficient Chinese subjects. Am J Clin Nutr 92: 525-531.
25. Meyer HA, Hollenbach B, Stephan C, Endermann T, Morgenthaler NG, et al. (2009) Reduced serum selenoprotein P concentrations in German prostate cancer patients. Cancer Epidemiol Biomarkers Prev 18: 2386-2390.
26. Hollenbach B, Morgenthaler NG, Struck J, Alonso C, Bergmann A, et al. (2008) New assay for the measurement of selenoprotein P as a sepsis biomarker from serum. J Trace Elem Med Biol 22: 24-32.
27. Hoeflich J, Hollenbach B, Behrends T, Hoeg A, Stosnach H, et al. (2011) The choice of biomarkers determines the selenium status in young German vegans and vegetarians. Br J Nutr 104: 1601-1604.
28. Townsend A, Featherstone A, Chery CC, Vanhaecke F, Kirby J, et al. (2004) Increased selenium concentrations in seronorm trace elements serum (level 2). Clin Chem 50: 1481-1482.
29. Xia Y, Hill KE, Byrne DW, Xu J, Burk RF, (2005) Effectiveness of selenium supplements in a low-selenium area of China. Am J Clin Nutr 81: 829-834.
30. Combs GF, Jackson MI, Watts JC, Johnson LK, Zeng H, et al. (2012) Differential responses to selenomethionine supplementation by sex and genotype in healthy adults. Br J Nutr 1-12.
31. Schomburg L, Köhrle J, (2008) On the importance of selenium and iodine metabolism for thyroid hormone biosynthesis and human health. Mol Nutr Food Res 52: 1235-1246.
32. Rasmussen LB, Hollenbach B, Laurberg P, Carle A, Hog A, et al. (2009) Serum selenium and selenoprotein P status in adult Danes- 8-year followup. J Trace Elem Med Biol 23: 265-271.
33. Muecke R, Schomburg L, Buentzel J, Kisters K, Micke O, (2010) Selenium or no selenium-that is the question in tumor patients: a new controversy. Integr Cancer Ther 9: 136-141.
34. Thomson CD, (2004) Assessment of requirements for selenium and adequacy of selenium status: a review. Eur J Clin Nutr 58: 391-402.
35. Rayman MP, (2008) Food-chain selenium and human health: emphasis on intake. Br J Nutr 100: 254-268.
36. Broadley MR, White PJ, Bryson RJ, Meacham MC, Bowen HC, et al. (2006) Biofortification of UK food crops with selenium. Proc Nutr Soc 65: 169-181.
37. Hartikainen H, (2005) Biogeochemistry of selenium and its impact on food chain quality and human health. J Trace Elem Med Biol 18: 309-318.
38. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C, (2007) Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. Jama 297: 842-857.
39. Clark LC, Combs GF Jr, Turnbull BW, Slate EH, Chalker DK, et al. (1996) Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. Jama 276: 1957-1963.
40. Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, et al. (2011) Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 306: 1549-1556.
41. Dennert G, Zwahlen M, Brinkman M, Vinceti M, Zeegers MP, et al. (2011) Selenium for preventing cancer. Cochrane Database Syst Rev CD005195.
42. Forceville X, Vitoux D, Gauzit R, Combes A, Lahilaire P, et al. (1998) Selenium, systemic immune response syndrome, sepsis, and outcome in critically ill patients. Crit Care Med 26: 1536-1544.
43. Angstwurm MW, Engelmann L, Zimmermann T, Lehmann C, Spes CH, et al. (2007) Selenium in Intensive Care (SIC): results of a prospective randomized, placebo-controlled, multiple-center study in patients with severe systemic inflammatory response syndrome, sepsis, and septic shock. Crit Care Med 35: 118-126.
44. Toulis KA, Anastasilakis AD, Tzellos TG, Goulis DG, Kouvelas D, (2010) Selenium supplementation in the treatment of Hashimoto's thyroiditis: a systematic review and a meta-analysis. Thyroid 20: 1163-1173.
45. Schomburg L, (2011) Selenium, selenoproteins and the thyroid gland: interactions in health and disease. Nat Rev Endocrinol 8: 160-171.
46. Schrauzer GN, (2009) RE: Lessons from the selenium and vitamin E cancer prevention trial (SELECT). Crit Rev Biotechnol 29: 81.
47. Maehira F, Luyo GA, Miyagi I, Oshiro M, Yamane N, et al. (2002) Alterations of serum selenium concentrations in the acute phase of pathological conditions. Clin Chim Acta 316: 137-146.
48. Renko K, Hofmann PJ, Stoedter M, Hollenbach B, Behrends T, et al. (2009) Down-regulation of the hepatic selenoprotein biosynthesis machinery impairs selenium metabolism during the acute phase response in mice. Faseb J 23: 1758-1765.
49. Zachara BA, Gromadzinska J, Wasowicz W, Zbrog Z, (2006) Red blood cell and plasma glutathione peroxidase activities and selenium concentration in patients with chronic kidney disease: a review. Acta Biochim Pol 53: 663-677.
50. Suzuki KT, Kurasaki K, Okazaki N, Ogra Y, (2005) Selenosugar and trimethylselenonium among urinary Se metabolites: dose- and age-related changes. Toxicol Appl Pharmacol 206: 1-8.
51. Olson GE, Winfrey VP, Hill KE, Burk RF, (2008) Megalin mediates selenoprotein P uptake by kidney proximal tubule epithelial cells. J Biol Chem 283: 6854-6860.
52. Chiu-Ugalde J, Theilig F, Behrends T, Drebes J, Sieland C, et al. (2010) Mutation of megalin leads to urinary loss of selenoprotein P and selenium deficiency in serum, liver, kidneys and brain. Biochem J 431: 103-111.